Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban safety and effectiveness in elderly patients with atrial fibrillation or venous thromboembolism
ChiCTR-OPC-17012858Phase 4Recruiting
- Sponsor
- Xinhua Hospital
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of rivaroxaban in Atrial fibrillation (AFib), venous thromboembolism (VTE), deep vein thrombosis (DVT) and 1 more (2 cohorts), sponsored by Xinhua Hospital. Primary endpoint: major bleeding events. Started Oct 2017; status: recruiting.
02
Drugs
rivaroxaban
03
Conditions
Atrial fibrillation (AFib)venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on ChiCTR-OPC-17012858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPC-17012858.